Registry of Plasma Cell Dyscrasia
Longitudinal Data Registry of a Spectrum of Plasma Cell Dyscrasia with Long-term Follow-up
Shanghai Zhongshan Hospital · NCT06760052
This study is collecting and looking at health information from patients with plasma cell dyscrasia to better understand their disease and how it affects them.
Quick facts
| Study type | Observational |
|---|---|
| Enrollment | 2000 (estimated) |
| Ages | 19 Years to 99 Years |
| Sex | All |
| Sponsor | Shanghai Zhongshan Hospital (other) |
| Locations | 1 site (Shanghai, Shanghai Municipality) |
| Trial ID | NCT06760052 on ClinicalTrials.gov |
What this trial studies
This observational study aims to collect and analyze clinical data on patients diagnosed with plasma cell dyscrasia (PCD) at Zhongshan Hospital, Fudan University. It includes both historical data from 2007 and ongoing prospective data collection to assess patient outcomes and characteristics. The study focuses on understanding the clinical and genetic features of PCD in the Chinese population and aims to explore the relationship between these characteristics and the disease's pathogenesis. By documenting real-world clinical practices, the study seeks to identify distinct clonal evolution patterns among various subtypes of PCD.
Who should consider this trial
Good fit: Ideal candidates include patients with a pathological diagnosis of PCD, such as multiple myeloma or MGUS, who have complete medical records from 2007 to 2027.
Not a fit: Patients with severe mental illness or those deemed unsuitable for inclusion by the investigator may not benefit from this study.
Why it matters
Potential benefit: If successful, this study could enhance understanding of plasma cell dyscrasia and improve patient management and treatment strategies.
How similar studies have performed: While this study builds on existing knowledge of plasma cell dyscrasia, it focuses on a specific population and may provide novel insights into the disease.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: Patients with pathological diagnosis of PCD \[e.g.: symptomatic/asymptomatic multiple myeloma, monoclonal gammopathy of undetermined significance (MGUS), POEMS syndrome, light chain (AL) amyloidosis) from 2007 to 2027 in Zhonshan Hospital. Patients who had complete diagnostic, treatment and follow-up records. With fully comprehension and signature of the informed consent form (ICF) for participation. Exclusion Criteria: Patients who refused to use reliable methods of contraception during pregnancy, lactation or age-appropriate period. Patients who suffered from severe mental illness. Patients who were deemed unsuitable for inclusion by the investigator.
Where this trial is running
Shanghai, Shanghai Municipality
- Zhongshan Hospital, Fudan University — Shanghai, Shanghai Municipality, China (RECRUITING)
Study contacts
- Study coordinator: Peng Liu, Ph.D
- Email: liu.peng@zs-hospital.sh.cn
- Phone: +862164041990 ext 2315
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.
Conditions: Multiple Myeloma and Other Plasma Cell Neoplasms